Latest Conference Articles

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

A breakdown of a new 12-month, phase 1b/2 assessment of the RNA therapy in patients with LCA10.

The prevention of type 2 diabetes is possible and has important clinical benefits.

Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.

An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.

A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

An investigator provides an update on the TEDDY study.

A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.

The monitor is approved for children and adults 4 years and older with diabetes.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.

Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.

Patients living in states that chose to expand Medicaid coverage might be seeking care earlier to prevent major leg amputation.

Results of the EXPERT study could help guide clinical decision making for GLP-1 RA-experienced patients.

Christopher Sorli, MD, describes the results of a study showing the need for simultaneous therapy rather than sequential.

Discussing a look at the current life expectancy of patients with T2DM with an assistant professor from the University of Florida’s College of Pharmacy.

Discussing the results of a phase 2 study from Diasome examining use of HDV-insulin in type 1 diabetics.

Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.

Bruce Bode, MD, discusses the results of a proof-of-concept study examining insulin and glucagon coadministration to prevent hypoglycemia and hyperglycemia in type 1 diabetics.

Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.

Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.

Hospitalization rates decrease 52% for patients with type 1 diabetes and 47% for patients with type 2 diabetes.

The intervention model can be used to help manage a variety of chronic diseases.

Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.

Survey findings highlight the psychological and psychosocial distress related to having diabetes.

More patients achieve international time in range consensus target of greater than 70% with the Advanced system.